Among patients with spondyloarthritis (SpA) who initiated or switched to either secukinumab or TNF inhibitors, secukinumab demonstrated greater 4‑year persistence, with fewer discontinuations owing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback